PL3613733T3 - Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu - Google Patents
Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-oluInfo
- Publication number
- PL3613733T3 PL3613733T3 PL18788031.5T PL18788031T PL3613733T3 PL 3613733 T3 PL3613733 T3 PL 3613733T3 PL 18788031 T PL18788031 T PL 18788031T PL 3613733 T3 PL3613733 T3 PL 3613733T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazol
- pyridin
- hydrochloride
- propyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170050924A KR101856444B1 (ko) | 2017-04-20 | 2017-04-20 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
| PCT/KR2018/004604 WO2018194416A1 (ko) | 2017-04-20 | 2018-04-20 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3613733T3 true PL3613733T3 (pl) | 2022-09-26 |
Family
ID=62184173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18788031.5T PL3613733T3 (pl) | 2017-04-20 | 2018-04-20 | Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11174240B2 (pl) |
| EP (1) | EP3613733B1 (pl) |
| JP (1) | JP6982097B2 (pl) |
| KR (1) | KR101856444B1 (pl) |
| CN (1) | CN110678455B (pl) |
| AU (1) | AU2018256259B2 (pl) |
| CA (1) | CA3060046C (pl) |
| CL (1) | CL2019002986A1 (pl) |
| CO (1) | CO2019011547A2 (pl) |
| ES (1) | ES2924798T3 (pl) |
| MX (1) | MX2019012454A (pl) |
| PL (1) | PL3613733T3 (pl) |
| RU (2) | RU2021116820A (pl) |
| WO (1) | WO2018194416A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101840702B1 (ko) * | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| KR102191180B1 (ko) * | 2019-05-31 | 2020-12-15 | 삼진제약주식회사 | 안질환 치료용 조성물 |
| US20230025836A1 (en) * | 2019-11-21 | 2023-01-26 | Samjin Pharmaceutical Co., Ltd. | Eye drop composition for preventing or treating eye disease |
| US20230201179A1 (en) * | 2020-04-08 | 2023-06-29 | Aptabio Therapeutics Inc. | Agent for treating contrast-induced acute kidney injury |
| KR102308991B1 (ko) * | 2020-04-08 | 2021-10-06 | 압타바이오 주식회사 | 조영제 유발 급성 신부전 치료제 |
| EP4137134A4 (en) * | 2020-04-13 | 2024-08-07 | Aptabio Therapeutics Inc | MEDICATION AGAINST PULMONARY FIBROSIS WITH PYRAZOLE DERIVATIVE |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO179282C (no) * | 1991-01-18 | 1996-09-11 | Rhone Poulenc Agrochimie | Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter |
| KR20020071931A (ko) | 2000-01-07 | 2002-09-13 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석 |
| WO2011028044A2 (ko) | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| WO2011028043A2 (ko) * | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| KR20120098462A (ko) * | 2011-02-28 | 2012-09-05 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| KR20120098489A (ko) * | 2011-02-28 | 2012-09-05 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물 |
| KR101633957B1 (ko) * | 2012-08-27 | 2016-06-27 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
| TW201603849A (zh) | 2014-07-01 | 2016-02-01 | 賽諾菲公司 | 響片配置及其藥物輸送裝置 |
-
2017
- 2017-04-20 KR KR1020170050924A patent/KR101856444B1/ko active IP Right Grant
-
2018
- 2018-04-20 AU AU2018256259A patent/AU2018256259B2/en active Active
- 2018-04-20 RU RU2021116820A patent/RU2021116820A/ru unknown
- 2018-04-20 MX MX2019012454A patent/MX2019012454A/es unknown
- 2018-04-20 CN CN201880034639.8A patent/CN110678455B/zh active Active
- 2018-04-20 EP EP18788031.5A patent/EP3613733B1/en active Active
- 2018-04-20 ES ES18788031T patent/ES2924798T3/es active Active
- 2018-04-20 US US16/605,380 patent/US11174240B2/en active Active
- 2018-04-20 WO PCT/KR2018/004604 patent/WO2018194416A1/ko unknown
- 2018-04-20 CA CA3060046A patent/CA3060046C/en active Active
- 2018-04-20 JP JP2019557483A patent/JP6982097B2/ja active Active
- 2018-04-20 PL PL18788031.5T patent/PL3613733T3/pl unknown
- 2018-04-20 RU RU2019132946A patent/RU2754255C2/ru active
-
2019
- 2019-10-17 CO CONC2019/0011547A patent/CO2019011547A2/es unknown
- 2019-10-18 CL CL2019002986A patent/CL2019002986A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019132946A3 (pl) | 2021-04-19 |
| EP3613733A1 (en) | 2020-02-26 |
| US11174240B2 (en) | 2021-11-16 |
| CA3060046C (en) | 2021-08-31 |
| WO2018194416A1 (ko) | 2018-10-25 |
| JP6982097B2 (ja) | 2021-12-17 |
| BR112019022002A2 (pt) | 2020-05-12 |
| MX2019012454A (es) | 2019-12-19 |
| RU2021116820A (ru) | 2021-06-22 |
| CN110678455A (zh) | 2020-01-10 |
| CN110678455B (zh) | 2022-08-16 |
| AU2018256259A1 (en) | 2019-11-07 |
| JP2020517661A (ja) | 2020-06-18 |
| EP3613733B1 (en) | 2022-07-20 |
| CA3060046A1 (en) | 2018-10-25 |
| KR101856444B1 (ko) | 2018-05-10 |
| EP3613733A4 (en) | 2020-11-18 |
| RU2754255C2 (ru) | 2021-08-31 |
| RU2019132946A (ru) | 2021-04-19 |
| ES2924798T3 (es) | 2022-10-11 |
| CO2019011547A2 (es) | 2020-02-18 |
| AU2018256259B2 (en) | 2020-06-18 |
| US20210122726A1 (en) | 2021-04-29 |
| CL2019002986A1 (es) | 2020-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263429A (en) | Crystalline forms of a triazolopyrimidine compound | |
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane | |
| PL3613733T3 (pl) | Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu | |
| HK1252845A1 (zh) | 勞拉替尼游離碱的結晶形式 | |
| IL280821A (en) | Heterocycline compound | |
| IL269626A (en) | Crystalline salt forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | |
| IL283368A (en) | The tricyclic compound | |
| PT3643718T (pt) | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 | |
| HUE066360T2 (hu) | Eravaciklin kristályformái | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| EP3660003C0 (en) | HETEROCYCLIC COMPOUND | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| EP3693368C0 (en) | HETEROCYCLIC COMPOUND | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| SG11202009356RA (en) | Heterocyclic compound | |
| HK1246786A1 (zh) | 吡咯並吡啶化合物的結晶形式 | |
| GB201507036D0 (en) | Crystalline enzyme inhibitor compound | |
| SG11202108905UA (en) | Crystalline form of an avibactam derivative | |
| ZA201907792B (en) | Heterocyclic compound | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| HK1252841A1 (zh) | 噻吩並嘧啶化合物的鹽酸鹽的結晶形式 | |
| EP3704109C0 (en) | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM III OF TIPIRACIL HYDROCHLORIDE | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| GB201915908D0 (en) | Crystalline forms of entrectinib | |
| SG11202105355XA (en) | Crystalline salts of corydalmine |